Laquinimod highlights from Teva Investor Day December 11

Laquinimod highlights from Teva Investor Day December 11 
LUND, SWEDEN -- (Marketwire) -- 12/12/12 --  Active Biotech's (NASDAQ
OMX NORDIC: ACTI) partner Teva Pharmaceutical Industries Ltd. hosted
yesterday, December 11, 2012, an investor meeting. Teva has a license
to develop and commercialize
Active Biotech's molecule laquinimod. 
Laquinimod highlights from the meeting: 
- Laquinimod stands to fulfill an unmet treatment need, both as
monotherapy and potentially in combination with other treatments. 
- The clinical development program of laquinimod is ongoing. Teva
continues to actively assess the best options for the next phase of
clinical development.
Several clinical trials may be initiated as
early as 2013: 
- A third Phase III clinical trial of laquinimod in
relapsing-remitting multiple
sclerosis (RRMS) (CONCERTO). 
- Phase III clinical trial of laquinimod in progressive MS. 
- Phase II clinical trial of laquinimod in Huntington's disease. 
- Phase II clinical trial of laquinimod in combination with COPAXONE
for RRMS. 
- Clinical trials of laquinimod in combination with other MS
treatments. 
- Clinical trials of laquinimod for the treatment of additional
neurodegenerative diseases. 
For further information please see www.tevapharm.com. 


 
 
Active Biotech AB (publ)
Tomas Leanderson
President & CEO

 
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company
with focus on autoimmune/inflammatory diseases and cancer. Projects in
or entering
pivotal phase are laquinimod, an orally administered small
molecule with unique
immunomodulatory properties for the treatment of
multiple sclerosis, TASQ for
prostate cancer as well as ANYARA for
use in cancer targeted therapy, primarily
of renal cell cancer. In
addition, laquinimod is in Phase II development for
Crohn's and
Lupus. An additional project in clinical development is the
orally
administered compound 57-57 for Systemic Sclerosis. Please
visit www.activebiotech.com for more information. 


 
 
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

 
Active Biotech is obligated to publish the information contained in
this press
release in accordance with the Swedish Securities Market
Act. This information
was provided to the media for publication 8:30
a.m. CET on December 12, 2012. 
Laquinimod highlights from Teva Investor Day December 11: 
http://hugin.info/1002/R/1664247/539857.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Active Biotech via Thomson Reuters ONE 
[HUG#1664247] 
For further information, please contact:
Hans Kolam
CFO
Phone: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com